{"id":61259,"date":"2026-03-25T14:59:48","date_gmt":"2026-03-25T06:59:48","guid":{"rendered":"https:\/\/flcube.com\/?p=61259"},"modified":"2026-03-25T14:59:48","modified_gmt":"2026-03-25T06:59:48","slug":"clover-bio-reports-positive-scb-1019-phase-i-data-rsv-pref-vaccine-demonstrates-superior-booster-response-vs-gsks-arexvy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61259","title":{"rendered":"Clover Bio Reports Positive SCB\u20111019 Phase I Data \u2013 RSV PreF Vaccine Demonstrates Superior Booster Response vs. GSK’s Arexvy"},"content":{"rendered":"\n

Clover Biopharmaceuticals Ltd.<\/strong> (HKG: 2197<\/a>) announced additional positive Phase I data<\/strong> from its US clinical trial<\/strong> evaluating SCB\u20111019<\/strong>, a prefusion F protein (PreF) RSV vaccine candidate<\/strong>, in a head\u2011to\u2011head booster setting against GSK’s Arexvy<\/strong> \u2013 demonstrating 60\u201180% higher neutralizing antibody titers<\/strong> with heterologous SCB\u20111019 boosting<\/strong> vs. homologous Arexvy boosting in elderly subjects previously vaccinated with Arexvy.<\/p>\n\n\n\n

Clinical Data Snapshot \u2013 Phase I Booster Study<\/h2>\n\n\n\n
Study Design Element<\/th>Detail<\/th><\/tr><\/thead>
Study Population<\/strong><\/td>Elderly subjects aged 60\u201185 years<\/strong><\/td><\/tr>
Prior Vaccination<\/strong><\/td>GSK’s Arexvy received \u22652 seasons prior<\/strong> to enrollment<\/td><\/tr>
Comparison<\/strong><\/td>SCB\u20111019 (heterologous boost)<\/strong> vs. Arexvy (homologous boost)<\/strong><\/td><\/tr>
Enrollment<\/strong><\/td>62 subjects<\/strong><\/td><\/tr>
Primary Endpoint<\/strong><\/td>Neutralizing antibody (nAb) geometric mean titers (GMTs)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Key Efficacy Results<\/h2>\n\n\n\n
Endpoint<\/th>SCB\u20111019 Heterologous Boost<\/th>Arexvy Homologous Boost<\/th>Clinical Advantage<\/th><\/tr><\/thead>
RSV A nAb GMTs<\/strong><\/td>~60\u201180% higher<\/strong><\/td>Baseline<\/td>Superior immunogenicity<\/td><\/tr>
RSV B nAb GMTs<\/strong><\/td>~60\u201180% higher<\/strong><\/td>Baseline<\/td>Superior immunogenicity<\/td><\/tr>
Peak Level Restoration (RSV A\/B)<\/strong><\/td>~120\u2011135%<\/strong> of primary Arexvy peak<\/td>~75%<\/strong> of primary Arexvy peak<\/td>Sustained superior response<\/strong> vs. waning homologous boost<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n
Dimension<\/th>RSV Vaccine Landscape<\/th>SCB\u20111019 Position<\/th><\/tr><\/thead>
Market Leaders<\/strong><\/td>Arexvy (GSK), Abrysvo (Pfizer) \u2013 approved for elderly adults<\/td>Next\u2011generation PreF design<\/strong> with superior booster potential<\/td><\/tr>
Booster Strategy<\/strong><\/td>Annual\/seasonal revaccination anticipated<\/td>Heterologous boosting<\/strong> \u2013 superior to homologous Arexvy revaccination<\/td><\/tr>
Differentiation<\/strong><\/td>Standard PreF vaccines show waning immunity<\/td>SCB\u20111019 restores and exceeds<\/strong> primary vaccination peak titers<\/td><\/tr>
Global Opportunity<\/strong><\/td>US\/EU elderly RSV market US$3\u20115 billion<\/strong> annually<\/td>Best\u2011in\u2011class booster<\/strong> positioning for annual revaccination market<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Outlook<\/h2>\n\n\n\n